MX2009012155A - Combinación farmacéutica sinérgica para el tratamiento de cáncer. - Google Patents
Combinación farmacéutica sinérgica para el tratamiento de cáncer.Info
- Publication number
- MX2009012155A MX2009012155A MX2009012155A MX2009012155A MX2009012155A MX 2009012155 A MX2009012155 A MX 2009012155A MX 2009012155 A MX2009012155 A MX 2009012155A MX 2009012155 A MX2009012155 A MX 2009012155A MX 2009012155 A MX2009012155 A MX 2009012155A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- pharmaceutical combination
- combination
- synergistic pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Nueva combinación farmacéutica que contiene un agente antineoplásico citotóxico seleccionado a partir del grupo formado por paclitaxel, docetaxel, doxorrubicina o gemcitabina o una sal farmacéuticamente aceptable de los mismos y al menos un inhibidor de cinasa dependiente de ciclina (CDK); en donde la combinación presenta un efecto sinérgico cuando se usa en el tratamiento del cáncer. La invención también se relaciona con un método para el tratamiento de cáncer, en el que se utiliza un cantidad terapéuticamente eficaz de la combinación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2007/051841 WO2008139271A2 (en) | 2007-05-15 | 2007-05-15 | A synergistic pharmaceutical combination for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009012155A true MX2009012155A (es) | 2010-01-15 |
Family
ID=40002696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009012155A MX2009012155A (es) | 2007-05-15 | 2007-05-15 | Combinación farmacéutica sinérgica para el tratamiento de cáncer. |
Country Status (18)
Country | Link |
---|---|
US (1) | US8822526B2 (es) |
EP (1) | EP2154971B1 (es) |
JP (1) | JP5688288B2 (es) |
KR (1) | KR101403100B1 (es) |
CN (1) | CN101677567B (es) |
AR (1) | AR066564A1 (es) |
AT (1) | ATE538652T1 (es) |
AU (1) | AU2007353129B2 (es) |
BR (1) | BRPI0721626A2 (es) |
CA (1) | CA2687204C (es) |
DK (1) | DK2154971T3 (es) |
ES (1) | ES2380129T3 (es) |
IL (1) | IL202014A (es) |
MX (1) | MX2009012155A (es) |
NZ (1) | NZ581183A (es) |
PT (1) | PT2154971E (es) |
TW (1) | TWI449525B (es) |
WO (1) | WO2008139271A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI461194B (zh) * | 2009-05-05 | 2014-11-21 | Piramal Entpr Ltd | 吡咯啶取代黃酮作為輻射致敏劑 |
US9763982B2 (en) | 2010-06-29 | 2017-09-19 | The Regents Of The University Of California | Depletion of cancer stem cells |
US20120009203A1 (en) * | 2010-06-29 | 2012-01-12 | Anahid Jewett | Depletion of cancer stem cells |
JP2013542979A (ja) * | 2010-11-19 | 2013-11-28 | ピラマル エンタープライジーズ リミテッド | パクリタキセルとcdk阻害剤の薬学的組合せ |
WO2012069972A1 (en) | 2010-11-19 | 2012-05-31 | Piramal Life Sciences Limited | A pharmaceutical combination for the treatment of breast cancer |
TW201242597A (en) | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
US20140142159A1 (en) | 2011-06-24 | 2014-05-22 | Piramal Enterprises Limited | Compounds for the treatment of cancers associated with human papillomavirus |
CA2917742C (en) * | 2013-07-12 | 2020-04-14 | Piramal Enterprises Limited | A pharmaceutical combination for the treatment of melanoma |
MX2017013383A (es) | 2015-04-20 | 2017-12-07 | Tolero Pharmaceuticals Inc | Prediccion de respuesta a alvocidib mediante perfilado mitocondrial. |
KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
CA3018932C (en) * | 2016-03-28 | 2021-10-26 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018187478A1 (en) * | 2017-04-04 | 2018-10-11 | University Of Miami | Biomarkers indicative of prostate cancer and treatment thereof |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
WO2020018037A2 (en) * | 2018-03-12 | 2020-01-23 | Yeditepe Universitesi | A chemotherapeutic agent comprising a combination of alexidine dihydrochloride and sodium pentaborate pentahydrate |
MX2021006544A (es) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer. |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
RU2710273C1 (ru) * | 2019-04-24 | 2019-12-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет имени Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Фармацевтическая композиция для лечения злокачественных новообразований |
CN114767669B (zh) * | 2022-05-20 | 2023-07-04 | 湖南省中医药研究院 | 一种P-gp抑制剂及其提取方法和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7271193B2 (en) | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
US7915301B2 (en) * | 2002-07-08 | 2011-03-29 | Piramal Life Science Limited | Inhibitors of cyclin dependent kinases and their use |
TWI331034B (en) * | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
AU2003276453A1 (en) * | 2002-11-06 | 2004-06-07 | Cyclacel Limited | Pharmaceutical composition comprising a cdk inhibitor and gemcitabine |
WO2005055952A2 (en) * | 2003-12-08 | 2005-06-23 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Synergistic anti-cancer compositions |
WO2006099193A2 (en) * | 2005-03-11 | 2006-09-21 | The Regents Of The University Of Michigan | Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
-
2007
- 2007-05-15 AT AT07735911T patent/ATE538652T1/de active
- 2007-05-15 CA CA2687204A patent/CA2687204C/en active Active
- 2007-05-15 PT PT07735911T patent/PT2154971E/pt unknown
- 2007-05-15 AU AU2007353129A patent/AU2007353129B2/en not_active Ceased
- 2007-05-15 DK DK07735911.5T patent/DK2154971T3/da active
- 2007-05-15 EP EP07735911A patent/EP2154971B1/en active Active
- 2007-05-15 ES ES07735911T patent/ES2380129T3/es active Active
- 2007-05-15 WO PCT/IB2007/051841 patent/WO2008139271A2/en active Application Filing
- 2007-05-15 NZ NZ581183A patent/NZ581183A/en unknown
- 2007-05-15 KR KR1020097025837A patent/KR101403100B1/ko not_active IP Right Cessation
- 2007-05-15 US US12/600,019 patent/US8822526B2/en active Active
- 2007-05-15 MX MX2009012155A patent/MX2009012155A/es active IP Right Grant
- 2007-05-15 BR BRPI0721626-2A patent/BRPI0721626A2/pt not_active IP Right Cessation
- 2007-05-15 CN CN2007800529954A patent/CN101677567B/zh active Active
- 2007-05-15 JP JP2010507996A patent/JP5688288B2/ja active Active
-
2008
- 2008-05-02 TW TW097116343A patent/TWI449525B/zh not_active IP Right Cessation
- 2008-05-14 AR ARP080102040A patent/AR066564A1/es unknown
-
2009
- 2009-11-09 IL IL202014A patent/IL202014A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2687204C (en) | 2015-11-24 |
AR066564A1 (es) | 2009-08-26 |
CN101677567B (zh) | 2013-06-19 |
TW200913991A (en) | 2009-04-01 |
ATE538652T1 (de) | 2012-01-15 |
KR101403100B1 (ko) | 2014-06-19 |
WO2008139271A3 (en) | 2009-04-23 |
PT2154971E (pt) | 2012-04-10 |
CN101677567A (zh) | 2010-03-24 |
BRPI0721626A2 (pt) | 2013-01-22 |
TWI449525B (zh) | 2014-08-21 |
WO2008139271A2 (en) | 2008-11-20 |
CA2687204A1 (en) | 2008-11-20 |
IL202014A0 (en) | 2010-06-16 |
US8822526B2 (en) | 2014-09-02 |
AU2007353129B2 (en) | 2014-02-20 |
IL202014A (en) | 2014-06-30 |
NZ581183A (en) | 2012-03-30 |
JP2010526862A (ja) | 2010-08-05 |
KR20100017763A (ko) | 2010-02-16 |
JP5688288B2 (ja) | 2015-03-25 |
EP2154971A4 (en) | 2010-05-19 |
ES2380129T3 (es) | 2012-05-08 |
US20100305057A1 (en) | 2010-12-02 |
EP2154971B1 (en) | 2011-12-28 |
DK2154971T3 (da) | 2012-04-02 |
AU2007353129A1 (en) | 2008-11-20 |
EP2154971A2 (en) | 2010-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009012155A (es) | Combinación farmacéutica sinérgica para el tratamiento de cáncer. | |
UA105390C2 (ru) | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК | |
WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
WO2009001359A3 (en) | Compositions and methods for inhibiting expression of pro-apoptotic genes | |
MX2008011633A (es) | Aminoquinolonas como inhibidores de gsk-3. | |
ECSP099634A (es) | Derivados de piridazinona útiles como inhibidores de glucano sintasa | |
WO2006091395A3 (en) | Inhibitors of akt activity | |
WO2008022256A3 (en) | Methods and compositions for preventing or treating age-related diseases | |
WO2007027527A3 (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
WO2008097640A3 (en) | Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer | |
UA92000C2 (en) | 1-benzylindole-2-carboxamide derivatives | |
UA95310C2 (ru) | Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака | |
BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação | |
WO2006110638A3 (en) | Inhibitors of akt activity | |
WO2008021038A3 (en) | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | |
WO2005099749A3 (en) | Methods for controlling angiogenesis and cell proliferation | |
WO2008029237A3 (en) | Combination therapies for rheumatoid arthritis | |
MA31305B1 (fr) | Administration hebdomadaire d'inhibiteurs de la dipeptidyle peptidase | |
MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
WO2007128086A3 (en) | Novel viral replication inhibitor | |
WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
WO2007097989A3 (en) | A composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer | |
WO2007131070A3 (en) | Compositions, dosage forms and methods of treating emesis | |
EP4108242A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING A MTOR SIGNALING INHIBITOR AS ACTIVE INGREDIENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights | ||
HC | Change of company name or juridical status |